News

Study shows treatment with SES in CTOs results in less restenosis compared with BMS

Posted on : 19 July 2010
Latest study results have shown that in chronic total occlusions, treatment with sirolimus-eluting stents leads to less restenosis at eight months compared with bare-metal stents.  Read more

Subclavian access feasible and safe with transcatheter device

Posted on : 19 July 2010
In patients undergoing transcatheter aortic valve implantation (TAVI), subclavian access may be feasible for those with anatomical or disease characteristics that discourage the standard femoral approach. The new technique appears to be associated with high rates of procedural success and few in-hospital complications, reports a study published online July 6, 2010, ahead of print in Circulation: Cardiovascular Interventions. Read more

New research reveals Genous Bio-engineered R stent is safe and effective in combination with drug-eluting balloon

Posted on : 19 July 2010
Six-month clinical follow-up data presented at the World Congress of Cardiology Scientific Sessions 2010 in June, showed the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please, B.Braun) followed by implantation of the Genous Bio-engineered R stent (OrbusNeich) for the percutaneous treatment of coronary artery stenosis. Read more

Longer length GORE VIABAHN Endoprosthesis receives CE mark approval

Posted on : 19 July 2010
The GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface has recently received CE mark approval. The new 25cm device is the longest length stent-graft available, designed to cover more of the lesion in the superficial femoral artery (SFA) potentially reducing the need for multiple devices.  Read more

Longer balloons provide physicians more options for treating peripheral artery disease

Posted on : 19 July 2010
Boston Scientific has announced that 22 new balloon sizes have been added to the PolarCath Peripheral Dilatation System, including balloon lengths of 120 and 150mm. Read more

Pre-market approval submission for the Zilver PTX Drug-Eluting Stent Platform

Posted on : 19 July 2010
Cook Medical has submitted its Pre-Market Approval (PMA) application to the FDA for the company's polymer-free Zilver PTX Drug-Eluting Peripheral Stent. Intended for use in patients with peripheral arterial disease (PAD) in the superficial femoral artery (SFA), is a self-expanding, highly durable nitinol stent that uses a proprietary, polymer-free technology to deliver a locally therapeutic dose of paclitaxel, an antiproliferative drug, to the target lesion. Read more

CE mark approval for the RePort Guide Catheter System

Posted on : 19 July 2010
Reverse Medical Corporation recently announced that it has received CE mark for its RePort Guide Catheter System, intended to provide intracranial access during interventional neurovascular procedures.  Read more

Pathway Medical Technologies receives FDA clearance for JETSTREAM atherectomy system

Posted on : 19 July 2010
The FDA has granted Pathway Medical Technologies 510(k) clearance to market JETSTREAM G3 SF (Small Fixed), the newest version of its peripheral revascularisation catheter for the treatment of peripheral vascular disease (PVD).  Read more

WhichMedicalDevice is a FREE resource created by clinicians for clinicians.

Registration is free and gives you unlimited access to all of the content and features of this website.

Find out more...

Please sign in to view this content...

I have forgotten my password
Not a Member?

Registration is free and gives you unlimited access to all of the content and features of Which Medical Device. Find out more...

Why Register

Which Medical Device is a community of clinicians sharing knowledge and experience of the devices and procedures we use on a daily basis. We ask that our members register with us so that we can maintain the unbiased and independent nature of our content. Registration is quick and free.

We do not make your details available to any third parties nor do we send unsolicited emails to our members. You can read our Privacy Policy here.